Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H16ClNO4 |
| Molecular Weight | 333.766 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(Cl)C=C1C(=O)NCCC2=CC=C(C=C2)C(O)=O
InChI
InChIKey=SWLAMJPTOQZTAE-UHFFFAOYSA-N
InChI=1S/C17H16ClNO4/c1-23-15-7-6-13(18)10-14(15)16(20)19-9-8-11-2-4-12(5-3-11)17(21)22/h2-7,10H,8-9H2,1H3,(H,19,20)(H,21,22)
| Molecular Formula | C17H16ClNO4 |
| Molecular Weight | 333.766 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Meglitinide (HB 699) is an antidiabetic compound. Meglitinide is a short-acting insulin secretagogue that targets one of the main defects that characterizes type 2 diabetes: the progressive loss of early phase prandial insulin secretion. It acts in a glucose-dependent manner to close adenosine triphosphate (ATP)-dependent potassium channels on the β-cell membrane, depolarize the β-cell, resulting in the opening of calcium channels, increased calcium influx and insulin secretion.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. | 2010-12-09 |
|
| Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. | 2010-10 |
|
| Point: postprandial glucose levels are a clinically important treatment target. | 2010-08 |
|
| Recommendations for management of diabetes during Ramadan: update 2010. | 2010-08 |
|
| Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. | 2010-06 |
|
| Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update. | 2010-05-10 |
|
| Approach to managing hypoglycemia in elderly patients with diabetes. | 2010-05 |
|
| Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin. | 2010-01 |
|
| Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. | 2010-01 |
|
| Aspects of insulin treatment. | 2010-01 |
|
| Pharmacologic management of the older patient with type 2 diabetes mellitus. | 2009-12 |
|
| Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. | 2009-11-09 |
|
| Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. | 2009-11 |
|
| Diabetes medications and body weight. | 2009-09 |
|
| Actos Now for the prevention of diabetes (ACT NOW) study. | 2009-07-29 |
|
| A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | 2009-07-20 |
|
| Fixed combination of repaglinide and metformin in the management of type 2 diabetes. | 2009-06-24 |
|
| Balancing risk and benefit with oral hypoglycemic drugs. | 2009-06 |
|
| Fixed-dose single tablet antidiabetic combinations. | 2009-06 |
|
| Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective. | 2009-05-05 |
|
| Postprandial hyperglycemia as an etiological factor in vascular failure. | 2009-04-29 |
|
| Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. | 2009-04 |
|
| Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. | 2009-01 |
|
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. | 2009-01 |
|
| Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone? | 2008-12 |
|
| Fatal metformin overdose presenting with progressive hyperglycemia. | 2008-08 |
|
| Association between serious ischemic cardiac outcomes and medications used to treat diabetes. | 2008-08 |
|
| Interaction of Aqueous Extract of Pleurotus pulmonarius (Fr.) Quel-Champ. with Glyburide in Alloxan Induced Diabetic Mice. | 2008-06 |
|
| Spermicidal activity of sulfonylureas and meglitinide analogues: role of intrasperm Ca2+ elevation. | 2008-03 |
|
| Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. | 2008-02 |
|
| Medication use and disease management of type 2 diabetes in Belgium. | 2008-01 |
|
| Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects. | 2008 |
|
| Type 2 diabetes and oral antihyperglycemic drugs. | 2008 |
|
| Review: meglitinide analogues reduce glucose levels in type 2 diabetes, but morbidity and mortality effects are unknown. | 2007-11-03 |
|
| Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. | 2007-11 |
|
| Are you up-to-date on diabetes medications? | 2007-07 |
|
| Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. | 2007-06 |
|
| A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. | 2007-06 |
|
| Meglitinide analogues for type 2 diabetes mellitus. | 2007-04-18 |
|
| Oral antidiabetic agents in type 2 diabetes. | 2007-04 |
|
| Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. | 2007-03 |
|
| Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004. | 2007-03 |
|
| Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. | 2007-02-19 |
|
| A review of nateglinide in the management of patients with type 2 diabetes. | 2007 |
|
| Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. | 2007 |
|
| Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. | 2007 |
|
| [Pharmacologic treatment of diabetes]. | 2006-12-23 |
|
| [Management of blood glucose--target of the management and its practice]. | 2006-11 |
|
| Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. | 2006-09 |
|
| Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. | 2006-07 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:47 GMT 2025
by
admin
on
Mon Mar 31 18:22:47 GMT 2025
|
| Record UNII |
8V6OK1I088
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98079
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
41214
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
8V6OK1I088
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
C030516
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
C66075
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
CHEMBL149930
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
SUB08713MIG
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
3884
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
54870-28-9
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
DTXSID40203356
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY | |||
|
100000081442
Created by
admin on Mon Mar 31 18:22:47 GMT 2025 , Edited by admin on Mon Mar 31 18:22:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
